All Oncology News

LY3537982, an investigative KRAS G12C inhibitor, demonstrated clinical efficacy across patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

The RAF dimer inhibitor BGB-3245 generated early efficacy signals with a tolerable safety profile in patients with advanced or refractory solid tumors harboring MAPK pathway mutations.

The allogeneic anti-CD70 CAR T-cell therapy ALLO-316 elicited signals of antitumor activity and showed a tolerable safety profile in patients with advanced or metastatic clear cell renal cell carcinoma.

Patients with African ancestry with colorectal cancer have fewer actionable gene mutations than those with European ancestry, leading to fewer targeted treatment options in this population.

The BCMA- and CD3-directed bispecific antibody REGN5459 led to fast onset, deep, and dose-dependent responses sustained over time, with a high frequency of manageable low-grade cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.

Preclinical data have demonstrated activity of a novel, small molecule CDK2 inhibitor INCB123667 in CDK2/cyclin E1 expressing cell lines prompting investigators to initiate a phase 1 study, and the agent may fill an unmet need for patients with cancers with primary or acquired CDK4/6 resistance.

The FDA has accepted a supplemental biologics license application seeking the approval of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

In a new study in the journal Nature Cancer, Dana-Farber Cancer Institute scientists shed new light on the mechanism that raises and lowers PSMA expression in prostate cancer cells.

The investigational tetravalent bispecific antibody AFM13 displayed clinical efficacy in heavily pretreated patients with CD30-positive relapsed/refractory peripheral T-cell lymphoma.

The combination of tafasitamab and lenalidomide followed by tafasitamab maintenance prolonged responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Perioperative durvalumab plus neoadjuvant platinum-based chemotherapy demonstrated a statistically significant improvement in pathologic complete response and event-free survival vs placebo plus chemotherapy in patients with resectable non–small cell lung cancer.

mRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.

Pembrolizumab plus cisplatin and gemcitabine produced a statistically significant and clinically meaningful improvement in overall survival vs placebo plus cisplatin and gemcitabine in previously untreated patients with advanced biliary tract cancer, according to data from the phase 3 KEYNOTE-966 trial.

Adjuvant treatment with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival vs active surveillance in patients with a high risk of hepatocellular carcinoma recurrence following curative-intent resection or ablation.

Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.

The antibody-drug conjugate trastuzumab deruxtecan led to durable responses and a tolerable safety profile in patients with HER2-expressing uterine carcinosarcoma.

During an OncLive® workshop titled Key Updates in the Management of Acute Myeloid Leukemia and Their Application in Clinical Practice, moderated by Naval Daver, MD, faculty reviewed updates to the classification of acute myeloid leukemia and its effects on the treatment paradigm and provided insight on the management of adverse-risk and secondary acute myeloid leukemia.

Shannon N. Westin, MD, MPH, FACOG, shares preclinical data that provided the impetus for the SOLAR trial of olaparib and selumetinib in patients with RAS-mutated gynecologic cancers, key findings from the dose-escalation and -expansion portions of the research, and next steps with the combination.

Julia E. McGuinness, MD, discusses the rationale for combining this novel PI3K inhibitor with fulvestrant and emphasized the importance of developing increasingly mutant-specific PI3K inhibitors in hormone receptor–positive breast cancer.

Though testicular cancer can impact males of any age, it generally affects men in their 20s and 30s. The average age at the time of diagnosis of testicular cancer is about 33, according to the American Cancer Society.

Thrombocytopenia is a common adverse effect associated with treatment with the MDM2 inhibitor milademetan in patients with sarcomas and other solid tumors, and the effects of thrombocytopenia can be mitigated with an intermittent dosing schedule and managed with dose interruptions or reductions.

The FDA has granted an orphan drug designation to TP-1287, an investigational oral CDK9 inhibitor, for the treatment of patients with Ewing sarcoma.

Investigators of an ongoing phase 1a/1b multicohort trial are studying whether addition of adaptive immune activators increases the benefit derived from anti–PD-1 antibodies in multiple tumor types.

The FDA has granted an orphan drug designation to OM-301 for the treatment of patients with multiple myeloma.

Jung-Yun Lee, MD, PhD, discusses the TRU-D trial within the context of prior negative trials to emphasize the need for more effective therapies in advanced-stage ovarian cancer, highlights key findings from TRU-D, and elaborates on future steps for this research.

The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma.

Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.

The US Oncology Network announced that Regional Cancer Care Associates entered into a strategic relationship with The Network effective April 1, 2023

The FDA has accepted for review a supplemental biologics license application for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.